Overcoming hurdles in developing successful drugs targeting chemokine receptors
Thomas J Schall1, Amanda E I Proudfoot
1ChemoCentryx, Inc., 850 Maude Avenue, Mountain View, California 94043, USA. tschall@chemocentryx.com
Abstract:
Chemokines and their receptors are central to the inflammatory process and are attractive therapeutic targets. Drugs that inhibit chemokine receptors are approved for the treatment of HIV infection and for stem cell mobilization, but none have been approved yet for the treatment of inflammatory and/or autoimmune diseases. We analyse the challenges of developing chemokine receptor antagonists, and propose that inappropriate target selection and ineffective dosing, not the 'redundancy' of the chemokine system, are the main barriers to their use as anti-inflammatory therapies. We highlight evidence suggesting that chemokine receptor inhibition will prove to be an effective therapy in inflammatory diseases.
Related Concept Videos
Drug Discovery: Overview
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Chemotaxis and Direction of Cell Migration

